If you're wondering why United Therapeutics (UTHR) shares are flying high Monday morning, it's because one of its drugs just passed a major test. The company announced that its nebulized treatment Tyvaso (treprostinil) hit the main goal in a big Phase 3 study for a tough lung disease called idiopathic pulmonary fibrosis, or IPF. That's the kind of news that gets investors excited, and the stock was up 16.5% to $608.84 in premarket trading, according to market data.

Here's what happened in the study, called TETON-1. The drug significantly improved a key measure of lung function—forced vital capacity—by 130.1 milliliters compared to a placebo. To put that in context, IPF is a chronic, progressive disease where lung tissue gets scarred up for unknown reasons (that's what "idiopathic" means), making it hard to breathe. There aren't a ton of great treatment options, so showing you can actually improve lung function is a big deal. The drug also reduced the risk of what doctors call "clinical worsening" in these patients.

Now, the results weren't perfect across the board. When you look at combined data from this TETON-1 study and another one called TETON-2, the treatment showed statistically significant effects on most secondary goals. But for overall survival at the 52-week mark, the data trended in favor of Tyvaso without hitting statistical significance. The silver lining? The treatment was well-tolerated, with no new safety flags popping up, which matters a lot when you're talking about a drug people might take long-term.

So what's next? United Therapeutics isn't wasting any time. The company plans to ask the FDA for a priority review of a supplemental application to add IPF to Tyvaso's label, and they aim to submit that by the end of this summer. They'll also be sharing more detailed results from TETON-1 and the combined analyses at the American Thoracic Society's big meeting in May 2026. Meanwhile, the company is running another study, TETON-PPF, to see if the drug can help patients with a related condition called progressive pulmonary fibrosis. It's worth noting that Tyvaso is already FDA-approved for a different lung condition, pulmonary arterial hypertension.

This isn't the only piece of good news for United Therapeutics lately. Earlier in March, the company shared positive results for another drug in its pipeline, ralinepag. That one is for pulmonary arterial hypertension (PAH), and in a Phase 3 trial, it cut the risk of clinical worsening events by 55% and boosted the odds of clinical improvement by 47% in mostly pre-treated patients. The company plans to submit a New Drug Application for ralinepag to the FDA in the second half of 2026. So, while today's spotlight is on Tyvaso and IPF, it seems United Therapeutics has more than one reason for investors to be paying attention.